// April 18, 2024
USP’s commitment to ESG considerations for a healthier, more sustainable world
At the U.S.
At the U.S.
The development of generic versions of innovator medicines is a global public health need.
In the U.S. and around the world, quality standards developed by the U.S.
In 2019, the World Health Organization (WHO) declared antimicrobial resistance (AMR) one of the t